The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
143
Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
daily dose: 3 tablets TID for 8 weeks.
The change from baseline in serum phosphate concentrations
Time frame: Week 8
Achievement of target serum phosphate level (2.7 to 4.6 mg/dL)
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Change in serum Calcium x Phosphor product
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Serum intact PTH level
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Phosphate excretion in urine
Time frame: Week 0, Week 4, Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Anjo, Aichi-ken, Japan
Unnamed facility
Nagoya, Aichi-ken, Japan
Unnamed facility
Nagoya, Aichi-ken, Japan
Unnamed facility
Nagoya, Aichi-ken, Japan
Unnamed facility
Nagoya, Aichi-ken, Japan
Unnamed facility
Seto, Aichi-ken, Japan
Unnamed facility
Toyohashi, Aichi-ken, Japan
Unnamed facility
Yatomi, Aichi-ken, Japan
Unnamed facility
Kamogawa, Chiba, Japan
Unnamed facility
Kisarazu, Chiba, Japan
...and 30 more locations